Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2001-11-09
2011-12-06
Kishore, Gollamudi (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
Reexamination Certificate
active
08071654
ABSTRACT:
Methods and compositions employing as active ingredient hepoxilins and hepoxilin analog useful for inhibiting thromboxane formation and antagonizing thromboxane activity. Methods and compositions employing these compounds provide treatment for a number of disease conditions.
REFERENCES:
patent: 5616607 (1997-04-01), Pace-Asciak et al.
patent: 5783564 (1998-07-01), Chaki et al.
patent: 6093741 (2000-07-01), Gosselin et al.
patent: 6391305 (2002-05-01), Feng et al.
patent: 6673785 (2004-01-01), Pace-Asciak
patent: 2159584 (1994-10-01), None
patent: 2159584 (1994-10-01), None
patent: 94/22848 (1994-10-01), None
patent: WO 94/22848 (1994-10-01), None
patent: 97/29751 (1997-08-01), None
patent: 99/59578 (1999-11-01), None
patent: 00/07589 (2000-02-01), None
patent: 01/10422 (2001-02-01), None
patent: 03/099285 (2003-12-01), None
Fink, Mitchell P. “Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis”. Journal of Antimicrobial Chemotherapy. 1998. vol. 41, Suppl. A. pp. 81-94.
Mitchell et al. “Cyclo-oxygenase-2: pharmacology, phycology, biochemistry and relevance to NSAID therapy”. British Journal of Pharmacology. 1999. vol. 128. pp. 1121-1132.
Reynaud et al. “Hepoxilin A3 Formation in the Rat Pineal Gland Selectively Utilizes (12S)-Hydroperoxyeicosatetraenoic Acid (HPETE), but Not (12R)-HPETE”. The Journal of Biological Chemistry. 1994. vol. 269, No. 39. pp. 23976-23980.
Brune et al (Journal of Biological Chemistry, 266:29 (1991) 19232).
Hamberg, M. et al., (1975), Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides, Proc. Natl. Acad. Sci. USA, v. 72, pp. 2994-2998.
Hamberg, M. et al., (1974), Prostaglandin Endoperoxides. Novel Transformations of Arachidonic Acid in Human Platelets Oric, Batk, Acad. Sci. USA, v. 71, pp. 3400-3404.
Diczfalusy, U. et al., (1980), Enzymatic Conversion of C21Endoperoxides to Thromboxanes and hydroxy acids Biochem. Biophys. Res. Commun., v. 94, pp. 1417-1423.
Hammarstrom, S. et al., (1998), Biosynthesis of Thromboxanes, Advances in Prostaglandin and Thromboxane Research, v. 6, pp. 267-274.
Fu, Z .Z. et al., (1992), Thromboxane/prostacyclin Balance in Type II Diabetes: Gliclazide Effects, Metabolism, v. 41, pp. 33-35.
Hendra, T. et al., (1989), Platelet Function, Platelet Prostanoids and Vascular Prostacyclin in Diabetes mellitus, Prostagl. Leuk. Essen. Fatty Acids., v. 35, pp. 197-212.
Webster, J. et al., (1981), Plasma Levels of 6-Oxo-PGF1α., the Hydrolysis Product of Prostacyclin, May Be Reduced in Diabetes, Clin. Pharmacol. Prostacyclin, pp. 113-115.
Fitzgerald, D. J. et al., (1990), Thromboxane A2synthesis in pregnancy-induced hypertension, Lancet, v. 335, pp. 751-754.
Himmelstein, S. I., et al., (1989), The role of thromboxane in two-kidney, one-clip Goldblatt hypertension in rats, Am. J. Physiol., v. 257, pp. 190-196.
Lüscher, T. F. (1990, Imbalance of Endothelium-derived Relaxaing and Contracting Factors, Am. J. Hypertens., v. 3, pp. 317-330.
Minuz, P. et al., (1990), Prostacyclin and Thromboxane Biosynthesis in Mild Essential Hypertension, Hypertension, v. 15, pp. 469-474.
Purkerson, M. Martin et al., (1985), Inhibitors of Thromboxane Synthesis and Ameliorate the Development of Hypertension in Wistar Rats with spontaneous Hypertension (SHR), Meeting of the American Society of Nephrology, Washington, D.C. USA.
Yamashita, W. et al., (1986), A Thromboxane Synthetase Antagonist Has Beneficial Effect on Renal Function in Nephritis With Hypertention, Forty-third Annual National Meeting of The American Federation for Clinical Research Washington, D.C. USA.
Fiedler, V. B. et al. (1989), Reduction of in vivo Coronary Artery Thrombosis by the Novel Thromboxane Antagonist (3R)-3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrandro-9-carbozolepropanoic Acid, Arzneimittelforschung, v. 39, pp. 1527-1530.
Parellada, P. P. et al., (1977), Action of Selective Inhibitor of Thromboxane Synthetase on Experimental Thrombosis Induced by Arachidonic Acid in Rabbits, Lancet, p. 40.
Randall, M. J. et al., (1982), Acute Arterial Thrombosis in Rabbits: Reduced Platelet Accumulation After Treatment With Thromboxane Synthetase Inhibitor Dazoxiben Hydrochloride, (UK-37, 24801), Thromb. Res. v. 28, pp. 607-616.
Silver, R. M. et al., (1995), Bacterial Lipopolysaccharide-mediated Fetal Death, J. Clin. Invest., v. 95, pp. 725-731.
Zaitsu, M. et al., (1999), Induction of cytosolic phospholipase A2and prostaglandin H2synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes, Eur. J. Haematol., v. 63, pp. 94-102.
Wolkow, P. P. et al., (1997) Pneumotoxicity of Lipopolysaccharide I Nitric Oxide Deficient Rats Is Limited by a Thromboxane Synthase Inhibitor, J. Physiol. Pharmacol., v. 48, pp. 645-653.
Coleman, R. A. et al., (1981), Comparison of the Actions of U-46619, Prostaglandin H2-Analogue, With Those of Prostaglandin H2and Thromboxane A2on Some Isolated Smooth Muscle Preparations, J. Pharmacol., v. 73, pp. 773-778.
Pollock, W. K., (1984) Thromboxane-induced phosphatidate formation in human platelets, Biochem., J. v. 219, pp. 833-842.
Tymkewycz, P. M. et al., (1991) Heterogeneity of thromboxane A2(TP-) receptors: evidence from antagonist but not agonist potency measurements, Br. J. Pharmacol., v. 102, pp. 607-614.
Heidemann, S. M. et al., (1997), Protective effects of a thromboxane synthetase inhibitor and continuous arteriovenous hemofiltration in rat endotoxic shock, Prostagl. Leuk. Essen. Fatty Acids, v. 56, pp. 473-478.
Kamilo, T. et al., (1993) An Improved and Convenient Procedure for the Synthesis of 1-Substituted Imidazoles, Chem. Pharm. Bull. (Tokyo), v. 31, pp. 1213-1221.
Pace-Asciak, C. R. et al., (1999), The Hepoxilins, Lipoxygenases and Their Metabolites- Biological Functions. Advances in Experimental Medicine and Biology, v. 447, Eds. S. Nigam and C.R. Pace-Asciak, Kluwer Academic/Plenum Publishers, New York, pp. 123-132.
Pace-Asciak, C. R. (1994), Hepoxilins: a review on their cellular actions, Biochim Biophys. Acta, v. 1215, pp. 1-8.
Pace-Asciak , C. R. et al., (1995), Hepoxilins: A Review on Their Enymatic Formation, Metobolism and Chemical Synthesis, Lipids, v. 30, pp. 107-114.
Laneuville, O. Reynaud et al., (1993), Hepoxilin A3inhibits the rise in free intracellular calcium evoked by formyl-methionyl-leucyl-phenylalanine, platelet-activating factor and leukotriene B4Biochem J., v. 295, pp. 393-397.
Dho, s. et al., (1990), Hepoxilin A3induces changes in cytosolic calcium, intracellular pH and membrane potential in human neutrophils, Biochem. J., v. 266, pp. 63-68.
Reynaud, D. et al., (1996), Hepoxilin A3-specific binding in human neutrophils, Biochem. J., v. 313, pp. 537-541.
Margalit, A. et al., Hepoxilin A3is the endogenous lipid mediator opposing hypotonic swellin g of intact human platelets, Proc. Natl. Acad. Sci. (USA), v. 90, pp. 2589-2592.
Belardetti, F. et al., (1988), Up-and down-modulation of single K+channel function by distinct second messengers, TINS, v. 11, pp. 232-238.
Belardetti, F. et al., (1989), Products of Heme-Catalyzed Transformation of the Arachidonate Derivative 12-HPETE Open S-Type K+Channels in Aplysia, Neuron, v. 3, pp. 497-505.
Urban, M. (2002), COX-2 Specific Inhibitors Offer Improved Advantages Over Traditional NSAIDs, Orthopedics, v. 23, pp. 761-764.
Everts et al., (2000), COX-2-Specific Inhibitors-the Emergence of a New Class of Analgesic and Anti-inflammatory Drugs, Clin. Rheumatol., v. 19, pp. 331-343.
Margalit et al., (1994), Endogenous hepoxilin A3, produced under short duration of high shear-stress, inhibits thrombin-induced aggregation in human platelets Biochim. Biophys. Acta, v. 1190, pp. 173-176.
Gilutz, H., (1997), Deactivation Mechanism of Platelets, Endothelium, v. 5, pp. 137-138.
Margalit et al., (1995), Low Regulatory Volume Decrease Rate in Platelets from Ischemic Patients: A Possible Role for Hepoxilin A3in Thrombogenicity, Platelets (Edinburg), Churchill Livingstone Medical Journals, GB, v. 6, pp. 371-376.
Pace-Asciak, C. R. (1999), Hepoxilin raise circulating in
Dinsmore & Shohl LLP
Kishore Gollamudi
Packard Benjamin
LandOfFree
Inhibitors of thromboxane formation and action does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of thromboxane formation and action, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of thromboxane formation and action will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314927